首页> 美国卫生研究院文献>Aging (Albany NY) >Tsukushi is a novel prognostic biomarker and correlates with tumor-infiltrating B cells in non-small cell lung cancer
【2h】

Tsukushi is a novel prognostic biomarker and correlates with tumor-infiltrating B cells in non-small cell lung cancer

机译:Tsukushi是一种新的预后生物标志物与非小细胞肺癌中的肿瘤渗透B细胞相关

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

A recent study has reported that tsukushi (TSKU) may be related to the development of lung cancer. However, few studies focused on if TSKU associated with the prognosis and immune infiltration cells in non-small cell lung cancer (NSCLC). The effect of TSKU expression on prognosis with NSCLC was analyzed in the PrognoScan database and validated in The Cancer Genome Atlas. The composition of tumor infiltrating cells was quantified by methylation and expression data. We combined levels of tumor infiltrating cells with TSKU to evaluate the survival of patients. The analysis of a cohort ({"type":"entrez-geo","attrs":{"text":"GSE31210","term_id":"31210"}}GSE31210, N=204) of lung cancer patients demonstrated that high TSKU expression was strongly associated with poor overall survival (P =1.90E-05). The combination of high TSKU expression and low infiltration B cells identified a subtype of patients with poor survival in NSCLC. Besides, the proportion of B cells in NSCLC patients with TSKU hypermethylation were higher than those patients with TSKU hypomethylation (P <0.001). Overall, high TSKU expression combined with low infiltration of B cells may associate with a poor prognosis of NSCLC patients. TSKU might be a potential prognostic biomarker involved in tumor immune infiltration in NSCLC.
机译:最近的一项研究报告说,Tsukushi(Tsku)可能与肺癌的发育有关。然而,很少的研究重点是Tsku与非小细胞肺癌(NSCLC)中的预后和免疫浸润细胞相关联。在预后数据库中分析了Tsku表达对NSCLC预后的影响,并在癌症基因组地图集中验证。通过甲基化和表达数据量化肿瘤渗透细胞的组成。我们将肿瘤浸润细胞的水平与Tsku进行综合评价患者的存活率。队列({“类型”:“atrez-geo”,“attrs”:{“text”:“gse31210”,“term_id”:“31210”}} gse31210,n = 204)肺癌患者所证明的高Tsku表达与整体存活差(P = 1.90E-05)强烈相关。高Tsku表达和低浸润B细胞的组合鉴定了NSCLC存活患者的患者亚型。此外,TSKU高甲基化患者的NSCLC患者的B细胞比例高于TSKU低甲基化的患者(P <0.001)。总体而言,高TSKU表达与B细胞的低浸润相结合,可以与NSCLC患者的预后差。 Tsku可能是潜在的预后生物标志物,参与NSCLC中的肿瘤免疫浸润。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号